Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus

Epilepsia

Volumn 56, Issue 4, 2015, Pages e44-e48

  Basha, Maysaa M ^a   Alqallaf, Abdulradha ^a   Shah, Aashit K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Continuous EEG; Intravenous anesthetic drugs; Status epilepticus treatment

Indexed keywords

BIOLOGICAL MARKER; KETAMINE; MIDAZOLAM; PENTOBARBITAL; PROPOFOL; ANESTHETIC AGENT; ANTICONVULSIVE AGENT;

ADULT; AGED; BETA RHYTHM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; FEMALE; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFRACTORY STATUS EPILEPTICUS; RETROSPECTIVE STUDY; REVIEW; SEIZURE; THETA RHYTHM; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; STATUS EPILEPTICUS;

ADULT; AGED; ANESTHETICS, DISSOCIATIVE; ANTICONVULSANTS; COHORT STUDIES; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84927578327     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12947     Document Type: Review

References (16)

1. Shorvon S, Ferlisi M,. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134: 2802-2818.
2. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205-210.
3. Wijdicks EF,. The multifaceted care of status epilepticus. Epilepsia 2013; 54 (Suppl. 6): 61-63.
4. Rosati A, L'Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology 2012; 79: 2355-2358.
5. Synowiec AS, Singh DS, Yenugadhati V, et al. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 2013; 105: 183-188.
6. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54: 1498-1503.
7. White PF, Way WL, Trevor AJ,. Ketamine-its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-136.
8. Zeiler FA, Teitelbaum J, West M, et al. The ketamine effect on ICP in traumatic brain injury. Neurocrit Care 2014; 21: 163-173.
9. Sheth RD, Gidal BE,. Refractory status epilepticus: response to ketamine. Neurology 1998; 51: 1765-1766.
10. Pruss H, Holtkamp M,. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008; 82: 219-222.
11. Yeh PS, Shen HN, Chen TY,. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure 2011; 20: 723-726.
12. Schuttler J, Stanski DR, White PF, et al. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987; 15: 241-253.
13. Hering W, Geisslinger G, Kamp HD, et al. Changes in the EEG power spectrum after midazolam anaesthesia combined with racemic or S- (+) ketamine. Acta Anaesthesiol Scand 1994; 38: 719-723.
14. Maksimow A, Sarkela M, Langsjo JW, et al. Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia. Clin Neurophysiol 2006; 117: 1660-1668.
15. Claassen J, Hirsch LJ, Mayer SA,. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 2003; 211: 37-41.
16. Wasterlain CG, Naylor DE, Liu H, et al. Trafficking of NMDA receptors during status epilepticus: therapeutic implications. Epilepsia 2013; 54 (Suppl. 6): 78-80.